Alvin Ginier
Optometrist · Huntington, WVNPI 1619085800
Payments from drug & device makers
What this record shows
27 manufacturers reported payments, led by Optos, Inc. at 56.5% of the total. 2025 is the largest year on record at $2,734, more than ten times the $38 reported in 2020.
Across 98 payments — averaging $41.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optos, Inc.$2K
- AstraZeneca$325
- Paratek Pharmaceuticals, Inc.$232
- Biogen$179
- Alcon$153
- Shield Therapeutics Inc$136
- plus $755 from 21 others
What the payments were for
- Speaking & faculty fees$2,31056%
- Food & beverage$1,78044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optos, Inc. | 1 | $2,310 |
| AstraZeneca(2 entities) | 19 | $325 |
| Paratek Pharmaceuticals, Inc. | 13 | $232 |
| Biogen | 11 | $179 |
| Alcon | 3 | $153 |
| Shield Therapeutics Inc | 6 | $136 |
| Novo Nordisk | 7 | $107 |
| Vifor Pharma, Inc. | 6 | $75 |
| Boehringer Ingelheim | 4 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| ABB Con-cise Optical Group LLC | 1 | $54 |
| Cvrx, Inc. | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Johnson & Johnson Vision Care, Inc. | 1 | $31 |
| Amgen | 2 | $27 |
| Travere Therapeutics, Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Argenx US, Inc. | 1 | $19 |
| Organon | 1 | $16 |
| Bausch & Lomb Americas Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$125
How this compares
$4,090 in reported general payments places this provider in the 85th percentile of 210 optometrist providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $73,967 |
| XiidraLifitegrast | 16 | $28,302 |
| Cyclosporine | 21 | $15,188 |
| Timolol Maleate | 118 | $5,722 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,468 |
| RhopressaNetarsudil Mesylate | 11 | $4,795 |
| Latanoprost | 298 | $3,991 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $2,653 |
| Prednisolone Acetate | 55 | $2,089 |
| Difluprednate | 13 | $1,499 |
| Brimonidine Tartrate | 29 | $1,436 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $983 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 76 | $920 |
| ErythromycinErythromycin Base | 27 | $378 |
| Dorzolamide Hcl | 25 | $312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $22 | $79,43560 claims |
| Bausch & Lomb Americas Inc.Xiidra | $13 | $28,30216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 optometrist providers in West Virginia.
Other optometrist in Huntington
- Jennifer StevensHuntington$8K
- William RatcliffHuntington$5K
- Chris RatcliffHuntington$5K
- Gregory MooreBuckhannon$28K
- Steven PotwinSaint Albans$24K
- Kayla CampbellBarboursville$16K
- Lee MooreCharles Town$10K
- Jill ShowalterVienna$10K
- Bryce PeekBarboursville$8K
- James FickClarksburg$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.